Angiotensin III: A physiological relevant peptide of the renin angiotensin system

Peptides

Volumn 46, Issue , 2013, Pages 26-32

  Yugandhar, Vudhya G ^a   Clark, Michelle A ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Aminopeptidase A; Angiotensin; Blood pressure; Cardiovascular; Renin angiotensin system; Sodium appetite; Vasopressin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN III; ATRIAL NATRIURETIC FACTOR; COLLAGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SODIUM; STRESS ACTIVATED PROTEIN KINASE; VASOPRESSIN;

ALDOSTERONE RELEASE; ARTICLE; ASTROCYTOSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; COLLAGEN SYNTHESIS; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLUID INTAKE; INTRACELLULAR SIGNALING; KIDNEY FUNCTION; MEAN ARTERIAL PRESSURE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT INTAKE; SODIUM APPETITE; SODIUM RETENTION; THIRST; VASODILATATION; VASOPRESSIN RELEASE;

AMINOPEPTIDASE A; ANGIOTENSIN; BLOOD PRESSURE; CARDIOVASCULAR; RENIN ANGIOTENSIN SYSTEM; SODIUM APPETITE; VASOPRESSIN;

ANGIOTENSIN III; ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; BLOOD VOLUME; CARDIOVASCULAR DISEASES; DIABETIC NEUROPATHIES; HUMANS; RATS; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; SODIUM; THIRST; VASOPRESSINS;

EID: 84885004860     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2013.04.014     Document Type: Review

References (80)

1. Abhold RH, Sullivan MJ, Wright JW, Harding JW. Binding, degradation andpressor activity of angiotensins II and III after aminopeptidase inhibition withamastatin and bestatin. J Pharmacol Exp Ther 1987;242:957-62.
2. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological roleand pharmacologic inhibition. J Manag Care Pharm 2007;13:9-20.
3. Avrith DB, Fitzsimons JT. Increased sodium appetite in the rat induced byintracranial administration of components of the renin-angiotensin system.J Physiol 1980;301:349-64.
4. Banegas I, Prieto I, Vives F, Alba F, de Gasparo M, Segarra AB, et al. Brainaminopeptidases and hypertension. J Renin Angiotensin Aldosterone Syst2006;7:129-34.
5. Banegas I, Prieto I, Vives F, Alba F, Duran R, Segarra AB, et al. Plasma aminopep-tidase activities in rats after left and right intrastriatal administration of6-hydroxydopamine. Neuroendocrinology 2004;80:219-24.
6. Batt CM, Klein EW, Harding JW, Wright JW. Pressor responses to amastatin,bestatin and Plummer's inhibitors are suppressed by pretreatment with theangiotensin receptor antagonist sarthran. Brain Res Bull 1988;21:731-5.
7. Blair-West JR, Carey KD, Denton DA, Madden LJ, Weisinger RS, Shade RE. Possi-ble contribution of brain angiotensin III to ingestive behaviors in baboons. AmJ Physiol Regul Integr Comp Physiol 2001;281:R1633-6.
8. Blair-West JR, Coghlan JP, Denton DA, Fei DT, Hardy KJ, Scoggins BA, et al. Adose-response comparison of the actions of angiotensin II and angiotensin IIIin sheep. J Endocrinol 1980;87:409-17.
9. Blair-West JR, Coghlan JP, Denton DA, Funder JW, Scoggins BA, WrightRD. The effect of the heptapeptide (2-8) and hexapeptide (3-8) frag-ments of angiotensin II on aldosterone secretion. J Clin Endocrinol Metab1971;32:575-8.
10. Blume A, Undeutsch C, Zhao Y, Kaschina E, Culman J, Unger T. ANG III inducesexpression of inducible transcription factors of AP-1 and Krox families in ratbrain. Am J Physiol Regul Integr Comp Physiol 2005;289:R845-50.
11. Bodineau L, Frugiere A, Marc Y, Inguimbert N, Fassot C, Balavoine F, et al. Orallyactive aminopeptidase A inhibitors reduce blood pressure: a new strategy fortreating hypertension. Hypertension 2008;51:1318-25.
12. Braun-Menendez E, Fasciolo JC, et al. The substance causing renal hypertension.J Physiol 1940;98:283-98.
13. Bumpus FM, Schwarz H, Page IH. Synthesis and pharmacology of the octapep-tide angiotonin. Science 1957;125:886-7.
14. Campbell WB, Brooks SN, Pettinger WA. Angiotensin II-and angiotensin 3-induced aldosterone release vivo in the rat. Science 1974;184:994-6.
15. Campbell WB, Pettinger WA. Organ specificity of angiotensin II and des-aspartylangiotensin II in the conscious rat. J Pharmacol Exp Ther 1976;198:450-6.
16. Caputo FA, Rowland NE, Fregly MJ. Angiotensin-related intakes of water andNaCl in Fischer 344 and Sprague-Dawley rats. Am J Physiol 1992;262:R382-8.
17. Chen CY, Huang WC. Pressor and renal effects of intracerebroventricu- larly administered angiotensins II and III in rats. Kidney Blood Press Res2000;23:95-105.
18. Clark MA, Nguyen C, et al. Distinct molecular effects of angiotensin II andangiotensin III in rat astrocytes. Int J Hypertens 2013;2013:1-8.
19. Clark MA, Nguyen C, Tran H. Angiotensin III induces c-Jun N-terminalkinase leading to proliferation of rat astrocytes. Neurochem Res 2012;37:1475-81.
20. Clark MA, Tran H, Nguyen C. Angiotensin III stimulates ERK1/2 mitogen-activated protein kinases and astrocyte growth in cultured rat astrocytes.Neuropeptides 2011;45:329-35.
21. Devynck MA, Pernollet MG, Matthews PG, Khosla MC, Bumpus FM, MeyerP. Specific receptors for des-Asp1-angiotensin II (("angiotensin III") in ratadrenals. Proc Natl Acad Sci USA 1977;74:4029-32.
22. Dzau VJ. Vascular wall renin-angiotensin pathway in control of the circulation.A hypothesis. Am J Med 1984;77:31-6.
23. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatoryactions of angiotensin-(1-7). Hypertension 1997;30:535-41.
24. Fink GD, Bruner CA. Hypertension during chronic peripheral and central infu-sion of angiotensin III. Am J Physiol 1985;249:E201-8.
25. Fitzsimons JT. The effect on drinking of peptide precursors and of shorterchain peptide fragments of angiotensin II injected into the rat's diencephalon.J Physiol 1971;214:295-303.
26. Fitzsimons JT. Angiotensin stimulation of the central nervous system. RevPhysiol Biochem Pharmacol 1980;87:117-67.
27. Fitzsimons JT. Angiotensin, thirst, and sodium appetite. Physiol Rev1998;78:583-686.
28. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: asystematic overview of data from individual patients, ACE-inhibitor myocardialinfarction collaborative group. Lancet 2000;355:1575-81.
29. Fournie-Zaluski MC, Coric P, Turcaud S, Bruetschy L, Lucas E, Noble F, et al.Potent and systemically active aminopeptidase N inhibitors designed fromactive-site investigation. J Med Chem 1992;35:1259-66.
30. Gammelgaard I, Wamberg S, Bie P. Systemic effects of angiotensinIII in conscious dogs during acute double blockade of therenin-angiotensin-aldosterone- system. Acta Physiol (Oxf) 2006;188:129-38.
31. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimentalhypertension: I. The production of persistent elevation of systolic blood pres-sure by means of renal ischemia. J Exp Med 1934;59:347-79.
32. Harding JW, Felix D. Angiotensin-sensitive neurons in the rat paraventricu-lar nucleus: relative potencies of angiotensin II and angiotensin III. Brain Res1987;410:130-4.
33. Harding JW, Felix D. The effects of the aminopeptidase inhibitors amastatinand bestatin on angiotensin-evoked neuronal activity in rat brain. Brain Res1987;424:299-304.
34. Harding JW, Felix D, Sullivan MJ, Camara CA, Erickson JB, Regulja I, et al. The piv-otal role at angiotensin III in the brain angiotensin system. Proc West PharmacolSoc 1987;30:11-5.
35. Harding JW, Jensen LL, Hanesworth JM, Roberts KA, Page TA, Wright JW. Releaseof angiotensins in paraventricular nucleus of rat in response to physiologicaland chemical stimuli. Am J Physiol 1992;262:F17-23.
36. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and managementof chronic heart failure in the adult: a report of the American College of Car-diology/American Heart Association Task Force on practice guidelines (writingcommittee to update the 2001 guidelines for the evaluation and managementof heart failure). J Am Coll Cardiol 2005;46:e1-82.
37. Karamyan VT, Gadepalli R, Rimoldi JM, Speth RC. Brain AT1 angiotensin recep-tor subtype binding: importance of peptidase inhibition for identification ofangiotensin II as its endogenous ligand. J Pharmacol Exp Ther 2009;331:170-7.
38. Kokje RJ, Wilson WL, Brown TE, Karamyan VT, Wright JW, Speth RC. Centralpressor actions of aminopeptidase-resistant angiotensin II analogs: challengingthe angiotensin III hypothesis. Hypertension 2007;49:1328-35.
39. Krishnan B, Smith TL, Dubey P, Zapadka ME, Torti FM, Willingham MC, et al.Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteo-clastogenesis. Prostate 2013;73:71-82.
40. Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone sys-tem blockade for cardiovascular diseases: current status. Br J Pharmacol2010;160: 1273-92.
41. Mann JF, Johnson AK, Ganten D. Plasma angiotensin II: dipsogenic levels andangiotensin-generating capacity of renin. Am J Physiol 1980;238:R372-7.
42. Marc Y, Llorens-Cortes C. The role of the brain renin-angiotensin sys-tem in hypertension: implications for new treatment. Prog Neurobiol2011;95:89-103.
43. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological andpathological effects in the cardiovascular system. Am J Physiol Cell Physiol2007;292:C82-97.
44. Ng KK, Vane JR. Conversion of angiotensin I to angiotensin II. Nature1967;216:762-6.
45. Padia SH, Kemp BA, Howell NL, Gildea JJ, Keller SR, Carey RM. Intrarenalangiotensin III infusion induces natriuresis and angiotensin type 2 receptortranslocation in Wistar-kyoto but not in spontaneously hypertensive rats.Hypertensions 2009;53:338-43.
46. Page IH, Helmer OM. A crystalline pressor substance (angiotonin) result-ing from the reaction between renin and renin-activator. J Exp Med1940;71:29-42.
47. Park BM, Oh YB, Gao S, Cha SA, , Kim SH. Angiotensin III stimulateshigh stretch-induced ANP secretion via angiotensin type 2 receptor. Peptides2013;42:131-7.
48. Qadri F, Edling O, Wolf A, Gohlke P, Culman J, Unger T. Release of angiotensinin the paraventricular nucleus in response to hyperosmotic stimulation in con-scious rats: a microdialysis study. Brain Res 1994;637:45-9.
49. Qadri F, Wolf A, Waldmann T, Rascher W, Unger T. Sensitivity of hypothal-amic paraventricular nucleus to C-and N-terminal angiotensin fragments:vasopressin release and drinking. J Neuroendocrinol 1998;10:275-81.
50. Reaux A, de Mota N, Zini S, Cadel S, Fournie-Zaluski MC, Roques BP, et al.PC18, a specific aminopeptidase N inhibitor, induces vasopressin release byincreasing the half-life of brain angiotensin III. Neuroendocrinology 1999;69:370-6.
51. Reaux A, Fournie-Zaluski MC, David C, Zini S, Roques BP, Corvol P, et al.Aminopeptidase A inhibitors as potential central antihypertensive agents. ProcNatl Acad Sci USA 1999;96:13415-20.
52. Reaux A, Fournie-Zaluski MC, Llorens-Cortes C. Angiotensin III: a central reg-ulator of vasopressin release and blood pressure. Trends Endocrinol Metab2001;12:157-62.
53. Reaux-Le Goazigo A, Iturrioz X, Fassot C, Claperon C, Roques BP, Llorens-CortesC. Role of angiotensin III in hypertension. Curr Hypertens Rep 2005;7:128-34.
54. Ruiz-Ortega M, Lorenzo O, Egido J. Angiotensin III increases MCP-1 and activatesNF-kappaB and AP-1 in cultured mesangial and mononuclear cells. Kidney Int2000;57:2285-98.
55. Shanmugam S, Corvol P, Gasc JM. Angiotensin II type 2 receptor mRNA expres-sion in the developing cardiopulmonary system of the rat. Hypertension1996;28:91-7.
56. Skeggs Jr LT, Lentz KE, Kahn JR, Shumway NP, Woods KR. The amino acidsequence of hypertensin, II. J Exp Med 1956;104:193-7.
57. Soubrier F, Cambien F. Renin-angiotensin system genes as candidate genes incardiovascular diseases. Trends Cardiovasc Med 1993;3:250-8.
58. Speth RC, Karamyan VT. The significance of brain aminopeptidases in the reg-ulation of the actions of angiotensin peptides in the brain. Heart Fail Rev2008;13:299-309.
59. Stadler T, Veltmar A, Qadri F, Unger T. Angiotensin II evokes noradrenalinerelease from the paraventricular nucleus in conscious rats. Brain Res1992;569:117-22.
60. Swanson LW, Sawchenko PE. Hypothalamic integration: organization of theparaventricular and supraoptic nuclei. Ann Rev Neurosci 1983;6:269-324.
61. Tharaux PL, Coffman TM. Transgenic mice as a tool to study therenin-angiotensin system. Contrib Nephrol 2001;135:72-91.
62. Tigerstedt R, Bergman PG. Niere and Kreislauf. Scand Arch Physiol1898;8:223-71.
63. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al.Angiotensin II receptors and angiotensin II receptor antagonists. PharmacolRev 1993;45:205-51.
64. Tonnaer JA, Engels GM, Voshart K, Wiegant VM, de Jong W. Binding ofangiotensins to rat brain tissue: structure activity relationship. Brain Res Bull1983;10:295-300.
65. Tonnaer JA, Wiegant VM, de Jong W, De Wied D. Central effects of angiotensinson drinking and blood pressure: structure-activity relationships. Brain Res1982;236:417-28.
66. Tseng CJ, Chou LL, Ger LP, Tung CS. Cardiovascular effects of angiotensin III inbrainstem nuclei of normotensive and hypertensive rats. J Pharmacol Exp Ther1994;268:558-64.
67. van Esch JH, Oosterveer CR, Batenburg WW, van Veghle R, Jan Dnaser AH. EurJ Pharmacol 2008;588:286-93.
68. Veltmar A, Culman J, Qadri F, Rascher W, Unger T. Involvement ofadrenergic and angiotensinergic receptors in the paraventricular nucleusin the angiotensin II-induced vasopressin release. J Pharmacol Exp Ther1992;263:1253-60.
69. Wamberg C, Plovsing RR, Sandgaard NC, Bie P. Effects of different angiotensinsduring acute, double blockade of the renin system in conscious dogs. Am JPhysiol Regul Integr Comp Physiol 2003;285:R971-80.
70. Wang HX, Zhang QF, Zeng XJ, Wang W, Tang CS, Zhang LK. Effects of angiotensinIII on protein, DNA, and collagen synthesis of neonatal cardiomyocytes andcardiac fibroblasts in vitro. J Cardiovasc Pharmacol Ther 2010;15:393-402.
71. Wilson WL, Roques BP, Llorens-Cortes C, Speth RC, Harding JW, Wright JW.Roles of brain angiotensins II and III in thirst and sodium appetite. Brain Res2005;1060:108-17.
72. Wright JW, Bechtholt AJ, Chambers SL, Harding JW. Angiotensin III and IV acti-vation of the brain AT1 receptor subtype in cardiovascular function. Peptides1996;17:1365-71.
73. Wright JW, Harding JW. Regulatory role of brain angiotensins in the con-trol of physiological and behavioral responses. Brain Res Brain Res Rev1992;17:227-62.
74. Wright JW, Harding JW. Important role for angiotensin III and IV in the brainrenin-angiotensin system. Brain Res Brain Res Rev 1997;25:96-124.
75. Wright JW, Jensen LL, Cushing LL, Harding JW. Heightened blood pressureresponsiveness to intracarotid infusion of angiotensins in the spontaneouslyhypertensive rat. Pharmacol Biochem Behav 1988;30:343-6.
76. Wright JW, Jensen LL, Roberts KA, Sardinia MF, Harding JW. Structure-functionanalyses of brain angiotensin control of pressor action in rats. Am J Physiol1989;257:R1551-7.
77. Wright JW, Mizutani S, Murray CE, Amir HZ, Harding JW. Aminopeptidase-induced elevations and reductions in blood pressure in the spontaneouslyhypertensive rat. J Hypertens 1990;8:969-74.
78. Wright JW, Morseth SL, Abhold RH, Harding JW. Pressor action and dipsogenic-ity induced by angiotensin II and III in rats. Am J Physiol 1985;249:R514-21.
79. Wright JW, Tamura-Myers E, Wilson WL, Roques BP, Llorens-Cortes C, Speth RC,et al. Conversion of brain angiotensin II to angiotensin III is critical for pressorresponse in rats. Am J Physiol Regul Integr Comp Physiol 2003;284:R725-33.
80. Zini S, Fournie-Zaluski MC, Chauvel E, Roques BP, Corvol P, Llorens-CortesC. Identification of metabolic pathways of brain angiotensin II and IIIusing specific aminopeptidase inhibitors: predominant role of angiotensinIII in the control of vasopressin release. Proc Natl Acad Sci USA 1996;93:11968-73.